<SEC-DOCUMENT>0001144204-17-024542.txt : 20170504
<SEC-HEADER>0001144204-17-024542.hdr.sgml : 20170504
<ACCEPTANCE-DATETIME>20170504161753
ACCESSION NUMBER:		0001144204-17-024542
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170504
DATE AS OF CHANGE:		20170504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		17814177

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v465942_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
May 4, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">001-12584</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Commission File No.)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>9605 Medical Center Drive, Suite 270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;(301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 - Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 4, 2017, Synthetic Biologics, Inc.,
a Nevada corporation, (the &ldquo;Registrant&quot;) issued the attached press release that included financial information for the
three months ended March 31, 2017. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information
contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any
of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;Exhibits.&nbsp;</FONT></TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit 99.1&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Press Release issued by Synthetic Biologics, Inc. dated May 4, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: May 4, 2017</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Steven A. Shallcross</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Steven A. Shallcross</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit No.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Press Release issued by Synthetic Biologics, Inc. dated May 4, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v465942_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg1img1_ex99-1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports First Quarter
2017 Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&mdash; Results from Phase 2b Proof-of-Concept
Study Exploratory Endpoints Demonstrate Ribaxamase Protects </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>and Preserves Gut Microbiome from
Ceftriaxone-mediated Dysbiosis &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B><I>-- Two Ribaxamase and Two
SYN-010 Presentations to be Included at</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B><I>Digestive Disease Week (DDW
2017) &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&mdash; Conference Call Today, May
4, 2017, at 4:30 p.m. (EDT) &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, May 4, 2017 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> <FONT STYLE="color: windowtext">(NYSE MKT: SYN), </FONT>a late-stage
clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, <FONT STYLE="color: windowtext">today
provided an operational update and reported financial results for the three months ended March 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;During the first quarter of 2017,
we announced several important clinical milestones which continue to drive momentum for Synthetic Biologics,&rdquo; said Jeffrey
Riley, President and Chief Executive Officer. &ldquo;We announced positive results from our Phase 2b proof-of-concept clinical
trial for ribaxamase demonstrating the achievement of the primary endpoint of significantly reducing the incidence of primary <I>Clostridium
difficile</I> infection (CDI). In addition, data from this study demonstrated that ribaxamase significantly lowered the incidence
of new colonization by vancomycin-resistant enterococci (VRE), compared to placebo. Most recently, we shared supportive data from
exploratory endpoints in this trial with the CDC demonstrating ribaxamase successfully protected and preserved the naturally occurring
composition of the gut microbiome from the dysbiotic effects of IV ceftriaxone, compared to placebo. These results position ribaxamase
as a leader in clinical development for microbiome-based interventions specifically designed to prevent the incidence of primary
CDI and antimicrobial resistance (AMR) amongst at-risk patients. We continue to analyze data from this study and expect to share
results in the coming months from several additional exploratory endpoints designed to evaluate ribaxamase&rsquo;s ability to prevent
the emergence and proliferation of AMR in the gut microbiome.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley continued, &ldquo;Since the
beginning of the first quarter, we also shared positive preclinical findings for SYN-005, our orphan drug program designed to
treat and prevent pertussis, which if translated to humans may provide a much-needed approach to protecting and treating the more
than 50 million global at-risk individuals, especially newborns in the developing world. Looking ahead, we are focused on building
upon the progress of the first quarter during the remainder of 2017. With the foundation of our Phase 2b/3 adaptive design pivotal
trial in place for SYN-010, intended to treat an underlying cause of IBS-C, we remain focused on solidifying the infrastructure
to support its continued successful clinical advancement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Microbiome-Focused Clinical Program
Progress</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SYN-004 &ndash; Prevention of <I>C.
difficile</I> infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial resistance (AMR):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Reported positive topline data from global Phase 2b proof-of-concept randomized, double-blind,
placebo controlled clinical trial of 412 patients (1Q 2017)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Achieved primary endpoint, demonstrating a statistically significant relative risk reduction of
71.4% (p=0.045) in CDI rates, compared to placebo</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">Demonstrated a significant reduction in new colonization by vancomycin-resistant enterococci (VRE) for
patients receiving ribaxamase, compared to placebo (p=0.0002)</P>


</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Reported supportive data from several exploratory endpoints from Phase 2b proof-of-concept clinical
trial demonstrating ribaxamase protected the gut microbiome from antibiotic-mediated dysbiosis in patients receiving ribaxamase,
compared to placebo</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Patients receiving ribaxamase demonstrated significantly better maintenance of and recovery of
the composition of the gut microbiome, compared to placebo</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Patients receiving ribaxamase demonstrated lower incidences of new colonization by VRE and other
opportunistic and potentially pathogenic microorganisms, compared to placebo</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">These results are consistent with protection of the gut microbiome and with ribaxamase&rsquo;s
mechanism of action during IV administration of ceftriaxone</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Expect to share results from several additional exploratory endpoints designed to evaluate ribaxamase&rsquo;s
ability to protect the gut microbiome from opportunistic bacteria and prevent the emergence of antimicrobial resistance (AMR) in
the gut microbiome (2H 2017)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Anticipate requesting end of Phase 2 meeting with FDA (2H 2017)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Plan to initiate Phase 3 clinical trial(s) (1H 2018)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SYN-010 &ndash; Treatment of irritable
bowel syndrome with constipation (IBS-C):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Confirmed key elements of Pivotal Phase
2b/3 clinical trial pursuant to consultations with the FDA (1Q 2017)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A 12-week, multi-center, double-blind, placebo-controlled, adaptive design clinical trial</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A study population of approximately 840 adult subjects diagnosed with IBS-C</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Evaluation of efficacy and safety of two dose strengths of SYN-010 (21 mg and 42 mg) compared to
placebo</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Conducted in approximately 150 clinical sites in North America</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Study subjects will be randomized in a 1:1:1 ratio, receiving either 21 mg of SYN-010, 42 mg of
SYN-010, or placebo</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Enrollment is open to all IBS-C patients; breath-methane will be measured at baseline to ensure
a comparable ratio of high-to-low breath methane IBS-C patients in each treatment arm</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">An interim futility analysis may be conducted when approximately 50% of patients in each dosing
arm have completed treatment</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SYN-005 &ndash; Treatment and Prevention
of Pertussis (whooping cough) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Reported positive preclinical research findings from neonatal non-human primate study designed
to determine if administration of hu1B7, one component of SYN-005, at two days of age could protect study animals from a subsequent
pertussis infection</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Control animals (n=6), challenged with <I>Bordetella pertussis</I> (<I>B. pertussis)</I> at five
weeks of age, demonstrated marked elevations in white blood cell counts and most exhibited behavioral signs of pertussis including
coughing and diminished activity</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Treatment animals (n=7), treated with hu1B7 at two days of age and then infected five weeks later,
had significantly lower peak white blood cell counts (p=0.004) that remained within the normal range or were only slightly elevated</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">All seven treatment animals that received prophylactic hu1B7 appeared healthy and none exhibited
any behavioral signs of pertussis</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics also announced that
four abstracts have been accepted for presentation at Digestive Disease Week <SUP>&reg;</SUP> 2017. Members of the Synthetic Biologics
team will present two posters on SYN-010 and two talks on ribaxamase at DDW <SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Digestive Disease Week <SUP>&reg;</SUP>
(DDW)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May 7, 2017</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Poster Su2012:</B> Poster Su2012:&nbsp;Increased pulmonary CO2 Excretion in Patients with Small
Intestinal Bacterial Overgrowth (SIBO): Possible Implications for COPD</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Session Number 7245 from 12:00 p.m. &ndash; 2:00 p.m. CDT</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Venue: McCormick Place, South Hall</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">Poster Su1562<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">: Initial Paradoxical
Peaks on Breath Testing (first sample high) do not Affect the Diagnostic Utility of the Spot-methane Breath Test</FONT></P>


</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Session Number 7130 from 12:00 p.m. &ndash; 2:00 p.m. CDT</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Venue: McCormick Place, South Hall</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Lecture 332g</B>: An Orally Delivered Beta-Lactamase Protects the Gut Microbiome from Antibiotic-Mediated
Damage and Mitigates the Propagation of Antibiotic-Resistance Genes in a Porcine Dysbiosis Model.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Session Number 3505 from 2:15 p.m. &ndash; 2:30 p.m. CDT</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Venue: McCormick Place, room S503</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May 9, 2017</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Lecture 874j</B>:&nbsp;SYN-004 (ribaxamase), an Oral &beta;-Lactamase, Prevented <I>Clostridium
difficile</I> Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome
Diversity in a Phase 2b Clinical Trial</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Session Number 5235 from 10:30 a.m. &ndash; 10:45 a.m. CDT</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Venue: McCormick Place, room S103</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Quarter Ended March 31, 2017 Financial
Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$2.1 million for the three months ended March 31, 2017, compared to $2.4 million for the same period in 2016. This decrease is
primarily the result of lower employee salary expense and related benefits costs along with reduced travel and legal expenses.
The charge related to stock-based compensation expense was $698,000 for the three months ended March 31, 2017, compared to $643,000
the same period in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses were
$6.0 million for the three months ended March 31, 2017, compared to $8.1 million for the same period in 2016. This decrease is
primarily the result of lower ribaxamase program costs associated with its clinical development program, as well as manufacturing
and research activities within our other microbiome-focused research and development activities. The charge related to non-cash
stock-based compensation expense was $437,000 for the three months ended March 31, 2017, compared to $409,000 for the same period
in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $5.1 million for the three
months ended March 31, 2017, compared to other expense of $0.5 million for the same period in 2016. Other income for the three
months ended March 31, 2017 is due to non-cash income of $5.1 million from the change in fair value of warrants. The decrease in
the fair value of the warrants was due to the decrease in our stock price from the prior quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents as of March 31,
2017 was $13.5 million, a decrease of $5.6 million from December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Thursday, May 4, 2017, at 4:30 p.m. (EDT). The dial-in information for the call is as follows, U.S. toll free:
1-888-347-5280 or International: +1 412-902-4280. Participants are asked to dial in 15 minutes before the start of the call to
register. The call will also be webcast over the Internet at <U>https://www.webcaster4.com/Webcast/Page/1096/20882</U>. An archive
of the call will be available for replay at the same URL, <U>https://www.webcaster4.com/Webcast/Page/1096/20882</U>, for 90 days
after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health
of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact
of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation
(IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used
intravenous (IV) beta-lactam antibiotics for the prevention of <I>C. difficile</I> infection (CDI), antibiotic-associated diarrhea
(AAD) and the emergence of antimicrobial resistance (AMR). The Company is also developing preclinical stage monoclonal antibody
therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria
(PKU). For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions,
and include statements regarding the results of Synthetic Biologics&rsquo; Phase 2b proof-of-concept clinical trial for ribaxamase
positioning ribaxamase as a leader in clinical development for microbiome-based interventions specifically designed to prevent
the incidence of primary CDI and antimicrobial resistance (AMR) amongst at-risk patients, the continued analysis of data from this
study, the expected sharing of results in the coming months from several additional exploratory endpoints designed to evaluate
ribaxamase&rsquo;s ability to prevent the emergence and proliferation of AMR in the gut microbiome, the ability of SYN-005 to provide
an approach to protecting and treating the more than 50 million global at-risk individuals for pertussis, the size of the pertussis
market, the continued clinical advancement of SYN-010 for the treatment of IBS-C, the anticipated requesting end of Phase 2 meeting
with FDA , expected initiation of Phase 3 clinical trials for SYN-004 and Phase2b/3 clinical trial for SYN-010 and the timing of
the initiation, and the potential benefits of SYN-004 and SYN-010. These forward-looking statements are based on management's expectations
and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are
difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those
set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially
from current expectations include, among others,&nbsp;Synthetic Biologics' product candidates demonstrating safety and effectiveness,
as well as results that are consistent with prior results, Synthetic Biologics' ability to initiate clinical trials and if initiated,
to complete them on time and achieve desired results and benefits, Synthetic Biologics' ability to successfully design a protocol
and a corresponding statistical analysis plan to support the execution of its pivotal clinical trials, Synthetic Biologics' clinical
trials continuing enrollment as expected, Synthetic Biologics' ability to obtain regulatory approvals for commercialization of
product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic Biologics' ability
to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace
and the successful development, marketing or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics'
products obsolete or non-competitive, Synthetic Biologics' ability to maintain its license agreements, the continued maintenance
and growth of Synthetic Biologics'&nbsp;patent estate, Synthetic Biologics becoming and remaining profitable, Synthetic Biologics'&nbsp;ability
to establish and maintain collaborations, Synthetic Biologics'&nbsp;ability to obtain or maintain the capital or grants necessary
to fund its research and development activities, a loss of any of Synthetic Biologics'&nbsp;key scientists or management personnel,&nbsp;and
other factors described in Synthetic Biologics' Annual Report on Form 10-K for the year ended December 31, 2016 and its other filings
with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes
no obligation to update any forward-looking statements contained in this release on account of new information, future events,
or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>For further information, please contact:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Feinstein Kean Healthcare (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@fkhealth.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR CLEAR="ALL">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>(in thousands, except share and per
share amounts)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">13,471</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">19,055</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,515</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">859</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">905</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deposits and other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,719</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">22,498</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,488</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,757</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Long-term deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">761</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,249</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,719</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">22,498</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Condensed Consolidated Statements of Operations</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Costs and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 9pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,090</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,426</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,059</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,155</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(498</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Other Expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,058</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,078</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(212</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(233</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,846</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(10,845</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.12</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding during the period - Basic and Dilutive</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">117,447,260</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,826,752</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pg1img1_ex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1img1_ex99-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 3P$# P$1  (1 0,1 ?_$ ,    (#  ,! 0$
M       )!P@*! 4&"P$# 0 !! ,! 0$             ! 4'" ,&"0$""A
M  8! P($ P8$!0$) 0   0(#! 4&!P 1"!()(1,4%3$B"D%1H=%2%F$R(Q="
M8C,D&#3P<8&Q<K)#<T8W$0 ! @0#!08# PD$"@(#   ! @, $00%(1(&,4$3
M% =187$B%0B!D3*AT2/PL4)28G(S4Q;!X1<)DJ)#<Y.S)#0U&(*RHU1%_]H
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MGW#\5=Q[&-TRGB:GWVFPM(O2E!D6.0&T&VDW4HG!1,\9VS)!3$TV,Q]-,)D
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M0)W'+BN2:QO1TU1(U0C96V.T@$W2LX<N0AV!C@ ])A;IM7/3X;AY@_?JOO\
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M3SI%?=54ZLM>S0J0P9R/'?(89([TK<"_!)B1NDFEDZSZBVJP.I*J1RI"W?\
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MB/I1* ")@UT9]XO2VHZA]+_5K2T7=06)U54VE(FIQ@IRU3:0,2<@2Z -I:D
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MLZIA0F'T-"Q:FYOZPNE5!\3&T]7)U%MMJPS@5$@>*R23\IF&JA0NNKDES$)
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M$N!G*V.S-2FF-KA*(ERE3(XC02NSD*K<JTS3*@TFV@G'_=R+)N4J4@F&Y^H
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MA*6S89_EOCS/TPG$-UC?CWDKEQ;895E8>0<RWJN.EWJ!DG XCHCA8%9=D)@
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M(E/QW_",;%LHZ=?$;3-8V$F<O"&QZ:X<(A3D9C4<O8/R7CU$H&?V"L/@AA$
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MTF&'V*NJ<TGJ%AY66E:KZ=R9E).9EP+).X!+:2=P B4?^$]S_;7[<]M)Y/\
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M*Y,7!ZF :#ZL,K:IJS)& 6E<7G[I:Z[;@7R"7;+KM5R0U1%-=LLJW73$<B5
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MB(B(ZQ]*E*5TVL:E$E1MC$R3,G\,;28S^XY"&^O6KT-I2E U!6     <96
MD .X0N:9Q+;^9G*_F[6I;,V4:1(X+:4*O8+0J%TFZW5:G-3E;?/B3,M$0ZJ1
MI4#R\>55QX@JH54X ;<J?1#=5IVX]2NH.J:&IN=PI';2BG;H0R^MIII;C2E9
MUH01G\Z05;R"1/!,K8V_7-A]OW1#IS=Z'3]EN-)J5RM?O)JJ1FHJ:EEFH0@M
M-.N@\*32RE&U*2E,QBO,W_$\)>*UC.B5[)=D97&_P=7AXFVVN/1<-VEBFV#-
M)J]F4T7?^Y*:142\T_7\PJ&,(_'5C-/TUTHK)24=[>34W=IA"'G4@@.+2D!2
MP#CYB)F>\F*&ZXN.F[OK"Y772%(Y0:7J:UUVEIEE*E,,K65(:)3Y2&P<HEA(
M 0C;E6RF(?E?E1?D_E#D!A:D6XU0;\4<]8\F9\<18U69-FYI)C;(2'>,F?NK
MF0 PN!<&*(;F4/\ TU"*DJQK]NIINH%>K7=?>+7:JG@BTU],MSDZ8I S)>;0
M0G.53S%?>3Y2%#I#T3J*"X=$;(UT:LVEM0ZBH15*U+9:YICU2X!:E<-=,\ZE
M:^$E$L@0#/!*?.E2%/FII%TZC5B.;*2Z."5V%*M<$D6B"=J5"-; >QD0CU%6
M"1)LW^Y J!C(@"OR")=M6RMP6+>P%OBI6&43>  #IRC\229I&?ZI),L<,(YF
M7]3:K[6J9HS;VC5NRI25*-,.(J3!*P%DL_PYK 4<OF$YQZ32R&B,V'<SXTO,
M0906R[5XQ0,;92D%7;]1LC_M*S?E^M>4CE_+^5LUL?29ZU$0*45A73#^0N_,
M+W2])'=)ZK5K6SLG^FKLX5.91Y6*M6*TF7TI?Q<1L&?B)&P3ZZ^SWJ]3Z]T8
MG0EY>']765H)0%'S5%$F0;<3/ZE,8-.;2$<)9^HR6%[@'W_@/YZJIRZNR+D\
MF8/< ^_\!_/1RZNR#DS'KZ)DZXXRLL7;Z'8I*LS\.]1?LWD<X423.JB;<47S
M0#>ED6:Y-R*HK$.FJF82F#8=/FG+Y?\ 25U9O6G*EVDN+#@6E2%$ D;EH^E:
M3L4E0(4)@B&'4NC;#K&T/6+4U(S66NH;*%)<2"0#O0J69M:3BE:"%)4 08:(
M7O&Y9"M>@-BJA'M0- 0_<?NDX6*%SY8$]>-< HJ]0F^?R@? 3J\-^GPU;4>\
MW68M?+JLUO-XR2XW$=X>:4L_!E/OR\67?**9GV!Z'-XYD7NYBR9\W X;/$RS
MGDX^R4L,W!G+=/&%=7S)EKR;;YV]WB9<3UILCT7TK)."E)UG A$4&[9ND!4&
M;%DW3(D@@F $22(4H!X:J3J.]7O5M[J-1:@>547>J7F<6<-TDI2!@E"$@)0D
M8)2 !%S=,Z.LFCK#3:9TY3IIK+2-Y&VTXR$R2I2CBI:U$J6M1)4HDF/(^X!]
M_P" _GIDY=79#[R9AV_9THCQS(YBRNX2.2/2:0N/8E4Z8@1P[.J%BG?)4$NP
M^E2*Q*;8?BIM]FKV^RK3#Z*B]ZN=!#!0U1MF6"C/C.R/[/X0,COCG3[^M24[
M-)8-$-*!JE+>KG1/%*9<!F8_:/&(_=BXU^PRMG_G!5++-L3JXQXVTV)7=F<I
M]3*P91GW[BQ1<&@50/+<)P,9Z"0>B'44HBW2-_J#M-NI-!JZA]=J&\7%LJTM
MIBB0HYAY'J]Y9=0V <"&4!IYPXB?"2?J,H"TOU ;Z7^W*NM%N="=8ZNN#H2$
MGSL6YA"6''E2Q27G.,PUL)'%6/I$,/U8Z*J0:((-$$&B"#1!!H@BM?+_  M/
M\B.-^4L,U>3B(:>O<1'QL?)SQGA8EJ=K/Q,JJ=X9@V>.P(9NP.4O0D<>L0W#
M;<=:5U%TS5ZRT5<-,T+C;575M!"5.3R A:5$JR@G8D[ <8E[H-U"M?2GJW9>
MH-Z9?J+9;'UN+;9R<504RZV C.I*9YE@F:A@#OBLV!N(N?(W/](S]R+R/C2;
MDL4XE5Q%CNKXJ@)V.CRP[E(6RTC8Y.Q'!X[> BHJ;H(4Q#*J 8!3*3H-HVDN
MG>KF-7TNK]:5M"Z_;[<:.G:I&W$IR':IQ3AS%4IX 2F9X 2,P=3>NO3&LZ7W
M'I?TGM-XIJ.]WT72NJ+D^RXOBI.8-L-L#(E$PD3)!"4D'.59A8#F_ABX\A.+
M>6,/4!2&2MUTCH!K#'L#Y>-ARJQMNK\VY]:];,I!= HLHQ3I$J)]S](> #N&
MV]4],W+6.@KAINT%H7&J0V$<112B:7FUG,H)41Y4F6!QE$7^W'J#8.E?6BQZ
M^U0*@V*WNOJ=#" X[)RE?93D0I: ?.XF<UB0F=THGO',"^JV/:)6)04!DJY3
M:O R(M5#+-A?1$(QCW8MU3II'50%PW-T&$I1,781 /AK;K)2.V^S4E!42X[%
M*TVJ1F,R$)29'"8F,#(81&.K;G37K55SO-%FY.KN%0\WF$E9'7EK3F ) 5E4
M)B9D=YA4&2N ?)=])\E,?XMROBF)P+RKOHWF^C:Z_8G>1ZRH_<-',Y&UU5@8
M89VBX,WZ$C+&*)DP -T1ZCF@"^=(]<//WRT6&XV]O26H*OCU'%;<-2UFR\1+
M12<A!E(%4L/U3,F[ND/<_P!(*:CTAJG6ECO;_4W1-LY.BY9]A-!4! 4EEQ\+
M_%24YIJ" 0%3/X@DD-NIU994NHU:G1JBRT=4ZY!UE@JX$!<*LH&,:Q;51<2^
M K'0:E$VWAU".K"VZA:MEO8MK!)8IV4-))VY6TA(GWR&,48O]XJ-0WVMO]6$
MIJZZK>J%A/TA;SBG% =P*C+NA:^(N,G,O!V9LMV"AWOC\?$^9<_S&5[7%S\3
M=I"[I0$S,;N8V)>-D&,2SE0KX 0O6"R)70=74)-0EIO0O4K2FIKC66JKLYT]
M<[PNK=0XA]3X;6O%*% )0E?#P$\P"L9RBW>N^L?M_P"I'3^Q6O4MLU2-<:?T
MNU;:9QEVC11E]IKRN.I45NK:X\R99%%O"6:&#9>QVQRYBS(>+Y)XK'LK_3K!
M4UY! GFK1X3<8X8)ODTA.F"QF:JQ5.@3% _3TB(;[ZF+4-G:U#8:RQ/J*&JR
MF<9*AB4\1)3F WRG.6^4HJUH35=3H76EJUE1MI=J+77L5(03(+X+B5E!,C+.
M 4SD93G(RA:>'^$/)IOD'C$YSQE'%$QC;B&VD4<9L<>P5@96JS*J0R,'%*6I
MS+$(Q0(S9,V_7Y._4"73TF,<RVH0TYTNURB[V)>K:^WNV/3B5"E33MN)==/#
M#:"\5^494A,\NV4L22J+>Z]]QG1UW2VLF>F=EOE/J[7BT&X+KGF%TU. Z7G!
M3):)62M:ERS[,TY@)"(8[G#%L?FW#^2<22C]:+99#I\W5E9-NF"JT:>49*(-
MWY$1,F"_HW(D4%/J+U@42[AOOJ:=4V%G5&G*W3M0LMLUM,XT5#$ISI("I;Y&
M1EOE**E].-:573K7EHUU1-)>J;57LU(;49!P-K"E()D99TS3FD93G(RE"S\6
M\&N4;#+7&:\9:R%@R4@.,0$K=>1I%8GHJTVVI)U9Q76\C9IEXTW>SK%NU8HH
M(&$&Y$BJF Q3B(JPA8.EFO&=16*[:CK;4Y26(<)L,-.(==:X):"G5J&+B0&P
ME/T@9C,'ZK@:T]R/1BIT-K#3FAK5J1FZ:R/,/FLJ&7*:FJ34I?4W3M(5Y&5J
M4\I:Q^(5% (*0 AC?(Z@3V5,!YBQK5S,"6.]8YME6@SRKA1I&EE)J'=,68OG
M2+=TJW:@NL'6<J:@E+X@4?AJ9M:VBKU!I&Y62@R<[5T3S2,Y(3F6@I3F(!($
MSB0#X14WI+JBV:*ZG6#5]Y#IM-MNU-4O!M(4YPVG4K7D25)"E2!D"H G>(X_
M&C'E@Q+Q]PWC*UFCSV2B8\K%7G#Q+E5Y&&DXB,0:.Q8.EF[15PU%5,>@YDDQ
M,'B)0UCT-9JS3NCK98KAD-=24333F0E2<R$@'*2 2)C R'A&3K!JJUZYZI:@
MUC9 Z+1<[K45#(=2$.<-UQ2DYTA2@E4CB I0!WF*)9@X9\GT\M\BKAQPRIC"
MMU+E57X6&R0TO\18EK-574;"KU]Q)4R1@BJ)>:LQ=KJ)&5Z1246$.G<B:H17
MJ/IKKM.HKS<]%7"@8M]_9;14BH0X76BALME3"F\)E*E$9I2)V8!466T%[@>C
M2]#:3L'5JR7FKOFB:IYV@51.L"GJ4N/)?2W5MO2,@M*$J"9A24 YI*4@L1PO
MCA/$&)L=XO3FI"Q_L2HPE:5GY159:0FG,8R20=RCDZZSA8#OG0'4 IE#B0#
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M]'*=T'*=T2+BC'EXS9?J]C7'40XF[18W94&Z1"&]''-"F+ZV:F')0,2/A8I
M15<+GV*4H;!N<Q2B_P"F-'7K6-\8T]8&2]<7U2&W*A/Z3CAEY6T#%2CX"9(!
MU36^J]-].],56K]6/II[+2(FHF69Q7Z#+23BMUP^5"!B3B9)!(V+\=L(5WCO
MB&HXJKI@=)P+(59F7%($5[!9'YO4SLXX(&XE,_?&-Y9!$?*0*FGN($#77#I]
MHJV]/=)4FE;9YFZ=$UKE(NNJ\SKJN]:B2!^BG*G8!' [JMU&NO5;7=?K6[#(
MJI<DTU.88IT>5EE)[$( S'#,LJ7*:HF9!LW;>;Z=!%#U"ZCE?RDR)BLX5V\Q
M=42@ J+'Z0W,.XB !]VMQ0VAN>0 9B29"4R=I/:>^(^<>=>R\52E94A(F29)
M&P#L [!A']]?<8X-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#
M1!!H@@T00:((-$$&B"#1!!H@@T00:((Z"TA5QKDT%U]A_:0QSH+%^Z!CPKOM
M/ECZSWD97:-"/\K?S//_ *?3\?#2.X>G\B[ZKP?3>&>+Q<O#R2\V?/Y<LMN;
M"6V'.R^LB[4YT]S/KG%3P.7S\?BS\G"X?XF>?TY/-/9"$>07";M^9 7?6/!O
M+G!F'IYT=5P:NKY<H%BQZX7/X]#1B>UI2]<3,IOX-EU6Z8>!&X!X:ICK7I+T
M,O;BZ_2>IK-:ZU1)X?.TSM,3W(+P6T)_J**1N1'3KI;[BO=+I9INT]2-":DO
M]L0 GCBV5K%<E(WJ6*8M/F6]Q"5JVJ=,*ROG%2X4Q=;VO+_%W(;!,YBIOZ5R
M3Q.8ZI W$%!C+)9*])$$P?X2D/L/V_;JO5WZ9U%L613W?3E:R#@IBZ4>/?D=
M=;4/A.+I:9ZVV+4#:>=L.L[54D8HJ[!<Y ]G$IV'VS+M)'A$($H5O.X*V U,
M*H90$P.?*N*"-P$1VZC.C7CTQ4P^TPFV#6J#3U0I8;XE%,F7_>T4OGS$I=\X
MD96J+$EHO$7 I G(6VY%7P3R>:?=*<6OP]PO)>7[)?)O)SBSAVM',11XJ]SM
MC*V6P4.L .1E P-J5C".1+N(>I?I 7XB4?AJ1-,]):*ZO(7?]1:<ME!^E.X4
MCSTNQ*&WLD_WG!+L.R(1U[[A%Z;IG&]'Z-UI?[N 0@(LUPIJ;-+ K>>I@X4S
MV\-E1.XC;&C;A=BGB#B"#E:QQNO>/LCVCT3%>^6R$O=5O-TE$^L2-EII6OOW
M8PT,9UU>G:I)H-"F^ &4W.-Y^E&G.EVF*-VW: K*&NK\J34O-U#-0^O]4N%M
M2LB)SRH 2@'8"9F.3/N%UOUYUY<F+SU<METM%FXBTT5,]1U-'2-F4U!D/H3Q
87<LL[BE+<(WA,DB\FI?BMT&B"#1!'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
